HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

XI-006

diminishes MDM4 promoter activity; structure in first source

Also Known As:

NSC207895

Networked: 4 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Oxazoles: 89
      - Oxadiazoles: 146
        XI-006: 4
  - Piperazines: 26
    - XI-006: 4

Experts

1.	Adwal, Alaknanda: 2 articles (08/2015 - 06/2015)
2.	Callen, David F: 2 articles (08/2015 - 06/2015)
3.	Clayer, Mark T: 2 articles (08/2015 - 06/2015)
4.	Farshid, Gelareh: 2 articles (08/2015 - 06/2015)
5.	Neuhaus, Susan J: 2 articles (08/2015 - 06/2015)
6.	Pishas, Kathleen I: 2 articles (08/2015 - 06/2015)
7.	Staudacher, Alexander H: 2 articles (08/2015 - 06/2015)
8.	Chopra, Harman: 1 article (01/2018)
9.	Contreras, Jamie: 1 article (01/2018)
10.	Khan, Zara: 1 article (01/2018)

Related Diseases

1.	Osteosarcoma (Osteogenic Sarcoma) 06/22/2015 - "As amplification of MDM4 is frequently observed in sarcomas, this study examined the therapeutic potential of XI-006 for the treatment of Ewing and osteosarcoma. " 06/22/2015 - "XI-006 treatment of Ewing and osteosarcoma cell lines (n = 11) resulted in rapid and potent apoptosis at low micro-molar concentrations specifically in Ewing sarcoma cell lines (48 hr IC50 0.099-1.61 μM). "
2.	Sarcoma (Soft Tissue Sarcoma) 06/22/2015 - "As amplification of MDM4 is frequently observed in sarcomas, this study examined the therapeutic potential of XI-006 for the treatment of Ewing and osteosarcoma. "
3.	Ewing Sarcoma (Sarcoma, Ewing) 08/27/2015 - "Erratum: XI-006 induces potent p53-independent apoptosis in Ewing sarcoma." 06/22/2015 - "Our findings suggest that XI-006 represents a novel therapeutic intervention for the treatment of Ewing sarcoma." 06/22/2015 - "XI-006 induces potent p53-independent apoptosis in Ewing sarcoma." 06/22/2015 - "XI-006 treatment of Ewing and osteosarcoma cell lines (n = 11) resulted in rapid and potent apoptosis at low micro-molar concentrations specifically in Ewing sarcoma cell lines (48 hr IC50 0.099-1.61 μM). "
4.	Prostatic Neoplasms (Prostate Cancer) 01/19/2018 - "We demonstrate that combinatorial inhibition of MDM2 and MDMX, with nutlin-3 and NSC207895 respectively, has a profound inhibitory effect on cell proliferation of androgen-responsive, wild-type TP53 gene carrying prostate cancer cells LNCaP and 22Rv1. "
5.	Neoplasms (Cancer) 01/01/2011 - "Here we report the identification of a benzofuroxan derivative [7-(4-methylpiperazin-1-yl)-4-nitro-1-oxido-2,1,3-benzoxadiazol-1-ium, NSC207895] that could inhibit MDMX expression in cancer cells through a reporter-based drug screening. "

Related Drugs and Biologics

1.	XI-006
2.	Androgens
3.	nutlin 3
4.	benzofuroxan